<p>加利福尼亚州门洛帕克，2026 年 1 月 13 日（全球新闻稿）——Sight Sciences, Inc.（纳斯达克代码：SGHT）（Sight Sciences 或公司），是一家专注于开发和商业化创新干预技术的眼科科技公司，旨在转变护理方式并改善患者生活，今天报告了截至 2025 年 12 月 31 日的第四季度和全年选择性初步未经审计的财务亮点。</p>
<p><strong>选择性初步财务亮点</strong></p>
<p>预计 2025 年第四季度总收入将在 2030 万美元至 2040 万美元之间，按估计中点计算，比去年同期增长 7%。</p>
<ul>
<li>外科青光眼收入预计将在 1960 万美元至 1970 万美元之间，按估计中点计算，比去年同期增长 5%。</li>
</ul>
<ul>
<li>干眼症收入预计约为 70 万美元，比去年同期增长约 130%。</li>
</ul>
<p>预计 2025 年全年总收入将在 7730 万美元至 7740 万美元之间，按估计中点计算，比去年下降 3%。</p>
<ul>
<li>外科青光眼收入预计将在 7560 万美元至 7570 万美元之间，按估计中点计算与去年持平。</li>
</ul>
<ul>
<li>干眼症收入预计约为 160 万美元，而 2024 年为 400 万美元。</li>
</ul>
<p>截至 2025 年 12 月 31 日，公司现金及现金等价物约为 9200 万美元，而截至 2025 年 9 月 30 日为 9240 万美元。</p>
<ul>
<li>本季度使用的现金总计约为 40 万美元，反映出持续的运营纪律。</li>
</ul>
<ul>
<li>本年度使用的现金总计约为 2800 万美元。</li>
</ul>
<p>“我们对第四季度的进展感到满意，包括与去年同期相比约 7% 的收入增长、强劲的现金管理、显著的干眼症报销里程碑以及持续的外科青光眼势头，” Sight Sciences 的联合创始人兼首席执行官保罗·巴达维（Paul Badawi）表示。“干眼症的关键成就包括建立两个医疗保险管理承包商的费用标准，以及我们报销的干眼症干预商业模式的早期积极验证。随着我们继续建设一家领先的干预眼科公司，我们对我们的增长前景、运营纪律以及在不需要额外股本的情况下实现现金流平衡的路径充满信心。”</p>
<p>本新闻稿中包含的公司 2025 年第四季度和全年初步未经审计的财务结果由管理层准备，基于目前可用的信息，并需完成公司的 2025 年审计。公司预计将在 2026 年 3 月公布完整的 2025 年第四季度和全年财务结果。</p>
<p><strong>财务披露建议</strong></p>
<p>公司根据美国公认会计原则（GAAP）报告其财务结果。本新闻稿中描述的选择性初步未经审计结果仅为估计，可能会在公司报告 2025 年第四季度和全年完整财务及业务结果之前进行修订。这些估计并不是公司 2025 年第四季度和全年财务结果的全面声明，实际结果可能因年终会计程序和调整的完成而与这些估计有重大差异，包括公司内部财务报告控制的执行、公司财务报表的准备和审计的完成，以及在正式发布 2025 年全年审计财务报表之前发生或识别的事件。</p>
<p><strong>关于 Sight Sciences</strong></p>
<p>Sight Sciences 是一家专注于开发和商业化创新和干预解决方案的眼科科技公司，旨在转变护理方式并改善患者生活。通过采用微创或非侵入性的方法，针对全球最常见眼病的根本原因，Sight Sciences 力求创造更有效的治疗范式，以提升患者护理并取代传统过时的方法。公司的 OMNI®外科系统和 OMNI® Edge 外科系统是无植入物的微创青光眼手术技术，适用于美国成人原发性开角型青光眼患者以降低眼内压。OMNI 外科系统已获得 CE 标记，用于施行施勒姆管的导管化和经腔内粘弹性扩张，以及切割小梁网以降低成人开角型青光眼患者的眼内压。青光眼是导致不可逆失明的全球主要原因。SION®外科系统是一种无刀、手动操作的设备，用于眼科手术中切除小梁网。公司的 TearCare®系统在美国获得 510(k) 批准，用于对因睑板腺疾病（MGD）导致的蒸发性干眼症成人患者进行局部热疗，帮助医生清除腺体阻塞，以解决干眼症的主要原因。有关更多信息，请访问 www.sightsciences.com。</p>
<p>Sight Sciences、Sight Sciences 标志、TearCare 和 SmartLids 是 Sight Sciences 在美国注册的商标。OMNI 和 SION 是 Sight Sciences 在美国、欧盟及其他地区注册的商标。</p>
<p>© 2026 Sight Sciences。保留所有权利。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿以及公司公开传播的其他声明和信息包含某些前瞻性声明，符合《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条的定义。公司希望这些前瞻性声明受到《1995 年私人证券诉讼改革法》中关于前瞻性声明的安全港条款的保护，并为遵守这些安全港条款而包含此声明。本新闻稿或在财报电话会议中所作的任何非历史事实的声明，包括关于我们信念和预期的声明，均为前瞻性声明，应作为此类声明进行评估。前瞻性声明包括但不限于关于 2025 年第四季度和全年预期财务和业务结果的声明；公司对其增长前景、运营纪律以及在不需要额外股本的情况下实现现金流平衡的路径的信心；以及关于 2025 年第四季度和全年财务和业务结果的完整公告的时间。这些声明通常包含 “预期”、“期望”、“建议”、“计划”、“相信”、“打算”、“估计”、“目标”、“项目”、“应该”、“可能”、“将”、“预测” 等类似表达。我们基于当前的预期、计划和在行业经验基础上所做的假设来制定这些前瞻性声明，以及我们对历史趋势、当前状况、预期未来发展和我们认为在当时情况下适当的其他因素的看法。尽管我们相信这些前瞻性声明是在做出时基于合理假设，但您应意识到，许多因素可能会影响我们的业务、运营结果和财务状况，并可能导致实际结果与前瞻性声明中表达的结果存在重大差异。这些声明并不是对未来表现或结果的保证。这些前瞻性声明受到并涉及众多风险、不确定性和假设，包括在我们向美国证券交易委员会提交的文件中讨论的 “风险因素” 标题下的因素，这些因素可能会在后续文件中不时更新，您不应对这些声明过度依赖。这些警示性声明仅在本新闻稿日期时作出。我们没有义务更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非适用法律要求。</p>
<p><strong>投资者联系：</strong></p>
<p>Philip Taylor</p>
<p>Gilmartin Group</p>
<p>415.937.5406</p>
<p>Investor.Relations@Sightsciences.com</p>
<p><strong>媒体联系：</strong></p>
<p>pr@SightSciences.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5ETXpOaU0zTXpVM05EUXhJekl5TURrM056RT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5ETXpOaU0zTXpVM05EUXhJekl5TURrM056RT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmEyZDdkMzYtMjA0My00MmYxLWI1ZWUtMWZmOGUyZDFjYzBlLTEyMjEzMjQtMjAyNi0wMS0xMy1lbg==/tiny/Sight-Sciences-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmEyZDdkMzYtMjA0My00MmYxLWI1ZWUtMWZmOGUyZDFjYzBlLTEyMjEzMjQtMjAyNi0wMS0xMy1lbg==/tiny/Sight-Sciences-Inc-.png"/></p>

SGHT

<p>Sight Sciences, Inc. 宣布了 2025 年第四季度和全年初步未经审计的财务亮点。第四季度收入预计在 2030 万美元到 2040 万美元之间，同比增长 7%；而全年收入预计在 7730 万美元到 7740 万美元之间，同比下降 3%。手术性青光眼的收入持平，干眼症的收入显著增长。公司报告现金及现金等价物约为 9200 万美元。首席执行官 Paul Badawi 表示对增长和运营纪律充满信心，目标是在不增加额外股本的情况下实现现金流收支平衡。完整的财务结果将在 2026 年 3 月公布</p>

<p>MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2025.</p>
<div class="lb-trans"><p>加利福尼亚州门洛帕克，2026 年 1 月 13 日（全球新闻稿）——Sight Sciences, Inc.（纳斯达克代码：SGHT）（Sight Sciences 或公司），是一家专注于开发和商业化创新干预技术的眼科科技公司，旨在转变护理方式并改善患者生活，今天报告了截至 2025 年 12 月 31 日的第四季度和全年选择性初步未经审计的财务亮点。</p>
</div><p><strong>Select Preliminary Financial Highlights</strong></p>
<div class="lb-trans"><p><strong>选择性初步财务亮点</strong></p>
</div><p>Fourth quarter 2025 total revenue is expected to be in the range of $20.3 million to $20.4 million, an increase of 7% at the estimated midpoint compared to the prior year period.</p>
<div class="lb-trans"><p>预计 2025 年第四季度总收入将在 2030 万美元至 2040 万美元之间，按估计中点计算，比去年同期增长 7%。</p>
</div><ul>
<li>Surgical Glaucoma revenues are expected to be in the range of $19.6 million to $19.7 million, an increase of 5% at the estimated midpoint compared to the prior year period.</li>
</ul>
<div class="lb-trans"><ul>
<li>外科青光眼收入预计将在 1960 万美元至 1970 万美元之间，按估计中点计算，比去年同期增长 5%。</li>
</ul>
</div><ul>
<li>Dry Eye revenues are expected to be approximately $0.7 million, an increase of approximately 130% compared to the prior year period.</li>
</ul>
<div class="lb-trans"><ul>
<li>干眼症收入预计约为 70 万美元，比去年同期增长约 130%。</li>
</ul>
</div><p>Full year 2025 total revenue is expected to be in the range of $77.3 million to $77.4 million, a decrease of 3% at the estimated midpoint compared to the prior year.</p>
<div class="lb-trans"><p>预计 2025 年全年总收入将在 7730 万美元至 7740 万美元之间，按估计中点计算，比去年下降 3%。</p>
</div><ul>
<li>Surgical Glaucoma revenues are expected to be in the range of $75.6 million to $75.7 million, flat at the estimated midpoint compared to the prior year.</li>
</ul>
<div class="lb-trans"><ul>
<li>外科青光眼收入预计将在 7560 万美元至 7570 万美元之间，按估计中点计算与去年持平。</li>
</ul>
</div><ul>
<li>Dry Eye revenues are expected to be approximately $1.6 million, compared to $4.0 million in 2024.</li>
</ul>
<div class="lb-trans"><ul>
<li>干眼症收入预计约为 160 万美元，而 2024 年为 400 万美元。</li>
</ul>
</div><p>The Company’s cash and cash equivalents as of December 31, 2025, were approximately $92 million, compared to $92.4 million as of September 30, 2025.</p>
<div class="lb-trans"><p>截至 2025 年 12 月 31 日，公司现金及现金等价物约为 9200 万美元，而截至 2025 年 9 月 30 日为 9240 万美元。</p>
</div><ul>
<li>Cash used in the quarter totaled approximately $0.4 million, reflecting continued operational discipline.</li>
</ul>
<div class="lb-trans"><ul>
<li>本季度使用的现金总计约为 40 万美元，反映出持续的运营纪律。</li>
</ul>
</div><ul>
<li>Cash used during the year totaled approximately $28 million.</li>
</ul>
<div class="lb-trans"><ul>
<li>本年度使用的现金总计约为 2800 万美元。</li>
</ul>
</div><p>“We are pleased with our progress in the fourth quarter, including approximately 7% revenue growth compared to the prior year period, strong cash management, significant Dry Eye reimbursement milestones, and continued Surgical Glaucoma momentum,” said Paul Badawi, Co-Founder and CEO of Sight Sciences. “Key Dry Eye achievements include the establishment of two Medicare Administrative Contractor fee schedules and positive early validation of our reimbursed interventional Dry Eye business model. As we continue building a leading interventional eye care company, we remain confident in our growth outlook, operational discipline, and path toward cash flow breakeven without requiring additional equity capital.”</p>
<div class="lb-trans"><p>“我们对第四季度的进展感到满意，包括与去年同期相比约 7% 的收入增长、强劲的现金管理、显著的干眼症报销里程碑以及持续的外科青光眼势头，” Sight Sciences 的联合创始人兼首席执行官保罗·巴达维（Paul Badawi）表示。“干眼症的关键成就包括建立两个医疗保险管理承包商的费用标准，以及我们报销的干眼症干预商业模式的早期积极验证。随着我们继续建设一家领先的干预眼科公司，我们对我们的增长前景、运营纪律以及在不需要额外股本的情况下实现现金流平衡的路径充满信心。”</p>
</div><p>The Company’s fourth quarter and full year 2025 preliminary, unaudited financial results included in this press release have been prepared by management and are based on information currently available to management and subject to the completion of the Company’s 2025 audit. The Company expects to announce complete fourth quarter and full year 2025 financial results in March 2026.</p>
<div class="lb-trans"><p>本新闻稿中包含的公司 2025 年第四季度和全年初步未经审计的财务结果由管理层准备，基于目前可用的信息，并需完成公司的 2025 年审计。公司预计将在 2026 年 3 月公布完整的 2025 年第四季度和全年财务结果。</p>
</div><p><strong>Financial Disclosure Advisory</strong></p>
<div class="lb-trans"><p><strong>财务披露建议</strong></p>
</div><p>The Company reports its financial results in accordance with U.S. generally accepted accounting principles (GAAP). The select preliminary, unaudited results described in this press release are estimates only and are subject to revision until the Company reports its full financial and business results for the fourth quarter and full year 2025. These estimates are not a comprehensive statement of the Company’s financial results for the fourth quarter and full year 2025 and actual results may differ materially from these estimates as a result of the completion of year-end accounting procedures and adjustments, including the execution of the Company’s internal control over financial reporting, the completion of the preparation and audit of the Company’s financial statements and the subsequent occurrence or identification of events prior to the formal issuance of the audited financial statements for the full year 2025.</p>
<div class="lb-trans"><p>公司根据美国公认会计原则（GAAP）报告其财务结果。本新闻稿中描述的选择性初步未经审计结果仅为估计，可能会在公司报告 2025 年第四季度和全年完整财务及业务结果之前进行修订。这些估计并不是公司 2025 年第四季度和全年财务结果的全面声明，实际结果可能因年终会计程序和调整的完成而与这些估计有重大差异，包括公司内部财务报告控制的执行、公司财务报表的准备和审计的完成，以及在正式发布 2025 年全年审计财务报表之前发生或识别的事件。</p>
</div><p><strong>About Sight Sciences</strong></p>
<div class="lb-trans"><p><strong>关于 Sight Sciences</strong></p>
</div><p>Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.</p>
<div class="lb-trans"><p>Sight Sciences 是一家专注于开发和商业化创新和干预解决方案的眼科科技公司，旨在转变护理方式并改善患者生活。通过采用微创或非侵入性的方法，针对全球最常见眼病的根本原因，Sight Sciences 力求创造更有效的治疗范式，以提升患者护理并取代传统过时的方法。公司的 OMNI®外科系统和 OMNI® Edge 外科系统是无植入物的微创青光眼手术技术，适用于美国成人原发性开角型青光眼患者以降低眼内压。OMNI 外科系统已获得 CE 标记，用于施行施勒姆管的导管化和经腔内粘弹性扩张，以及切割小梁网以降低成人开角型青光眼患者的眼内压。青光眼是导致不可逆失明的全球主要原因。SION®外科系统是一种无刀、手动操作的设备，用于眼科手术中切除小梁网。公司的 TearCare®系统在美国获得 510(k) 批准，用于对因睑板腺疾病（MGD）导致的蒸发性干眼症成人患者进行局部热疗，帮助医生清除腺体阻塞，以解决干眼症的主要原因。有关更多信息，请访问 www.sightsciences.com。</p>
</div><p>Sight Sciences, the Sight Sciences logo, TearCare, and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.</p>
<div class="lb-trans"><p>Sight Sciences、Sight Sciences 标志、TearCare 和 SmartLids 是 Sight Sciences 在美国注册的商标。OMNI 和 SION 是 Sight Sciences 在美国、欧盟及其他地区注册的商标。</p>
</div><p>© 2026 Sight Sciences. All rights reserved.</p>
<div class="lb-trans"><p>© 2026 Sight Sciences。保留所有权利。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with such safe harbor provisions. Any statements made in this press release or during the earnings call that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include, but are not limited to, statements concerning expected financial and business results for fourth quarter and full year 2025; the Company’s confidence in its growth outlook, operational discipline, and path toward cash flow breakeven without requiring additional equity capital; and timing for announcement of complete fourth quarter and full year 2025 financial and business results. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</p>
<div class="lb-trans"><p>本新闻稿以及公司公开传播的其他声明和信息包含某些前瞻性声明，符合《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条的定义。公司希望这些前瞻性声明受到《1995 年私人证券诉讼改革法》中关于前瞻性声明的安全港条款的保护，并为遵守这些安全港条款而包含此声明。本新闻稿或在财报电话会议中所作的任何非历史事实的声明，包括关于我们信念和预期的声明，均为前瞻性声明，应作为此类声明进行评估。前瞻性声明包括但不限于关于 2025 年第四季度和全年预期财务和业务结果的声明；公司对其增长前景、运营纪律以及在不需要额外股本的情况下实现现金流平衡的路径的信心；以及关于 2025 年第四季度和全年财务和业务结果的完整公告的时间。这些声明通常包含 “预期”、“期望”、“建议”、“计划”、“相信”、“打算”、“估计”、“目标”、“项目”、“应该”、“可能”、“将”、“预测” 等类似表达。我们基于当前的预期、计划和在行业经验基础上所做的假设来制定这些前瞻性声明，以及我们对历史趋势、当前状况、预期未来发展和我们认为在当时情况下适当的其他因素的看法。尽管我们相信这些前瞻性声明是在做出时基于合理假设，但您应意识到，许多因素可能会影响我们的业务、运营结果和财务状况，并可能导致实际结果与前瞻性声明中表达的结果存在重大差异。这些声明并不是对未来表现或结果的保证。这些前瞻性声明受到并涉及众多风险、不确定性和假设，包括在我们向美国证券交易委员会提交的文件中讨论的 “风险因素” 标题下的因素，这些因素可能会在后续文件中不时更新，您不应对这些声明过度依赖。这些警示性声明仅在本新闻稿日期时作出。我们没有义务更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非适用法律要求。</p>
</div><p><strong>Investor contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>Philip Taylor</p>
<div class="lb-trans"><p>Philip Taylor</p>
</div><p>Gilmartin Group</p>
<div class="lb-trans"><p>Gilmartin Group</p>
</div><p>415.937.5406</p>
<div class="lb-trans"><p>415.937.5406</p>
</div><p>Investor.Relations@Sightsciences.com</p>
<div class="lb-trans"><p>Investor.Relations@Sightsciences.com</p>
</div><p><strong>Media contact:</strong></p>
<div class="lb-trans"><p><strong>媒体联系：</strong></p>
</div><p>pr@SightSciences.com</p>
<div class="lb-trans"><p>pr@SightSciences.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5ETXpOaU0zTXpVM05EUXhJekl5TURrM056RT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyNDMzNiM3MzU3NDQxIzIyMDk3NzE="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmEyZDdkMzYtMjA0My00MmYxLWI1ZWUtMWZmOGUyZDFjYzBlLTEyMjEzMjQtMjAyNi0wMS0xMy1lbg==/tiny/Sight-Sciences-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MmEyZDdkMzYtMjA0My00MmYxLWI1ZWUtMWZmOGUyZDFjYzBlLTEyMjEzMjQtMjAyNi0wMS0xMy1lbg==/tiny/Sight-Sciences-Inc-.png"/></p>

Sight Sciences 宣布 2025 年第四季度和全年未经审计的财务亮点 | SGHT 股票新闻